Literature DB >> 11303026

Cytoplasmic domain of natriuretic peptide receptor C constitutes Gi activator sequences that inhibit adenylyl cyclase activity.

M Pagano1, M B Anand-Srivastava.   

Abstract

We have recently demonstrated that a 37-amino acid peptide corresponding to the cytoplasmic domain of the natriuretic peptide receptor C (NPR-C) inhibited adenylyl cyclase activity via pertussis toxin (PT)-sensitive G(i) protein. In the present studies, we have used seven different peptide fragments of the cytoplasmic domain of the NPR-C receptor with complete, partial, or no G(i) activator sequence to examine their effects on adenylyl cyclase activity. The peptides used were KKYRITIERRNH (peptide 1), RRNHQEESNIGK (peptide 2), HRELREDSIRSH (peptide 3), RRNHQEESNIGKHRELR (peptide 4), QEESNIGK (peptide X), ITIERRNH (peptide Y), and ITIYKKRRNHRE (peptide Z). Peptides 1, 3, and 4 have complete G(i) activator sequences, whereas peptides 2 and Y have partial G(i) activator sequences with truncated carboxyl or amino terminus, respectively. Peptide X has no structural specificity, whereas peptide Z is the scrambled peptide control for peptide 1. Peptides 1, 3, and 4 inhibited adenylyl cyclase activity in a concentration-dependent manner with apparent K(i) between 0.1 and 1 nm; however, peptide 2 inhibited adenylyl cyclase activity with a higher K(i) of about 10 nm, and peptides X, Y, and Z were unable to inhibit adenylyl cyclase activity. The maximal inhibitions observed were between 30 and 40%. The inhibition of adenylyl cyclase activity by peptides 1-4 was absolutely dependent on the presence of guanine nucleotides and was completely attenuated by PT treatment. In addition, the stimulatory effects of isoproterenol, glucagon, and forskolin on adenylyl cyclase activity were inhibited to different degrees by these peptides. These results suggest that the small peptide fragments of the cytoplasmic domain of the NPR-C receptor containing 12 or 17 amino acids were sufficient to inhibit adenylyl cyclase activity through a PT-sensitive G(i) protein. The peptides having complete structural specificity of G(i) activator sequences at both amino and carboxyl termini were more potent to inhibit adenylyl cyclase activity as compared with the peptides having a truncated carboxyl terminus, whereas the truncation of the amino-terminal motif completely attenuates adenylyl cyclase inhibition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303026     DOI: 10.1074/jbc.M101587200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide C receptor-mediated signalling.

Authors:  R A Rose; N Hatano; S Ohya; Y Imaizumi; W R Giles
Journal:  J Physiol       Date:  2007-01-04       Impact factor: 5.182

Review 2.  Natriuretic peptide C receptor signalling in the heart and vasculature.

Authors:  Robert A Rose; Wayne R Giles
Journal:  J Physiol       Date:  2007-11-15       Impact factor: 5.182

3.  Effects of natriuretic peptides on electrical conduction in the sinoatrial node and atrial myocardium of the heart.

Authors:  John Azer; Rui Hua; Pooja S Krishnaswamy; Robert A Rose
Journal:  J Physiol       Date:  2013-12-16       Impact factor: 5.182

4.  Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C.

Authors:  Emmanuel E Egom; Kimberly Vella; Rui Hua; Hailey J Jansen; Motahareh Moghtadaei; Iuliia Polina; Oleg Bogachev; Rhea Hurnik; Martin Mackasey; Sara Rafferty; Gibanananda Ray; Robert A Rose
Journal:  J Physiol       Date:  2015-01-12       Impact factor: 5.182

5.  New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease.

Authors:  Emmanuel Eroume-A Egom; Tiam Feridooni; Rebabonye B Pharithi; Barkat Khan; Haaris A Shiwani; Vincent Maher; Yassine El Hiani; Robert A Rose; Kishore Bs Pasumarthi; Hilaire A Ribama
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2017-09-01

Review 6.  B-type natriuretic Peptide and the right heart.

Authors:  Lok Bin Yap
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

7.  Bi-allelic Loss-of-Function Mutations in the NPR-C Receptor Result in Enhanced Growth and Connective Tissue Abnormalities.

Authors:  Eveline Boudin; Tjeerd R de Jong; Tim C R Prickett; Bruno Lapauw; Kaatje Toye; Viviane Van Hoof; Ilse Luyckx; Aline Verstraeten; Hugo S A Heymans; Eelco Dulfer; Lut Van Laer; Ian R Berry; Angus Dobbie; Ed Blair; Bart Loeys; Eric A Espiner; Jan M Wit; Wim Van Hul; Peter Houpt; Geert R Mortier
Journal:  Am J Hum Genet       Date:  2018-07-19       Impact factor: 11.025

8.  Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux.

Authors:  Cynthia F Bartels; Hulya Bükülmez; Pius Padayatti; David K Rhee; Conny van Ravenswaaij-Arts; Richard M Pauli; Stefan Mundlos; David Chitayat; Ling-Yu Shih; Lihadh I Al-Gazali; Sarina Kant; Trevor Cole; Jenny Morton; Valérie Cormier-Daire; Laurence Faivre; Melissa Lees; Jeremy Kirk; Geert R Mortier; Jules Leroy; Bernhard Zabel; Chong Ae Kim; Yanick Crow; Nancy E Braverman; Focco van den Akker; Matthew L Warman
Journal:  Am J Hum Genet       Date:  2004-05-14       Impact factor: 11.025

9.  Natriuretic peptide C receptor in the developing sheep lung: role in perinatal transition.

Authors:  Bobby Mathew; Christopher A D'Angelis; Satyan Lakshminrusimha; Peter A Nickerson; June J Sokolowski; Vasantha H S Kumar; Huamei Wang; Karen A Wynn; Bruce A Holm; Rita M Ryan
Journal:  Pediatr Res       Date:  2017-05-31       Impact factor: 3.756

10.  Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor.

Authors:  Sharmila D Chauhan; Holger Nilsson; Amrita Ahluwalia; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.